MBBS FRACP FRCPA DM
Phone: +61 3 9076 3393
Fax: +61 3 9076 2298
- Professor, Division of Blood Cancers
- Group Leader, Myeloma Research Group
- Head, Haematology Early Phase Clinical Research Unit
- Head, Malignant Haematology and Stem ell Transplantation Service
Andrew Spencer completed his medical training in clinical and laboratory haematology in 1992. Subsequently, he was awarded a LRF (UK) Fellowship and spent 3 years at The Royal Postgraduate Medical School, London, where he undertook research into B-cell clonality in chronic myeloid Leukaemia under the supervision of Professors John Goldman and Junia Melo and was awarded a Doctorate of Medicine from the University of London. Andrew moved to The Alfred Hospital in 1999 where he established an independent translational research program. In parallel he established a first-in-human and early phase haematology clinical research unit at The Alfred and was appointed Head of the Malignant Haematology & Stem Cell Transplantation Services in 2007.
Professor Spencer has secured research funding of more than $12 million via funding bodies, industry collaborations and philanthropy. He has >100 peer reviewed publications with citations in excess of 3300. Andrew serves on the scientific advisory boards of the International Myeloma Foundation (IMF), International Myeloma Working Group (IMWG) and the European Myeloma Network (EMN). He is a Director of the Australasian Leukaemia & Lymphoma Group (ALLG) and the International Myeloma Society (IMS). He is the immediate past-President of the Haematology Society of Australia & New Zealand (HSANZ).
Research Interests and Projects
The research program of Professor Andrew Spencer aims to (1) identify more effective and rationale novel therapeutic strategies for MM through the identification of drug resistance processes and/or biomarkers of drug responsiveness (employing transcriptional and proteomic studies in mouse models and primary tumours) with rapid translational of synergistic drug combinations into early phase investigator-initiated clinical trials, and (2) identify mechanisms of MM disease progression, with a particular focus on the role of the cell surface phosphatase CD45, and (3) explore the role of different modalities of minimal residual disease (MRD) detection in MM to optimise their utility in clinical practice.
Dawson M, Opat S, Taouk Y, Donovan M, Monaghan K, Horvath N, Roberts A, Prince HM, Hertzberg M, McLean C, Spencer A. Clinical and immunohistochemical features associated with response to bortezomib in patients with multiple myeloma. Clinical Cancer Research 2009; 15: 714-722. (IF 7.34)
Spencer A, Prince HM, Roberts AW. Prosser IW, Bradstock KF, Coyle L, Gill DS, Horvath N, Reynolds J, Kennedy N. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem cell transplant (ASCT) procedure. Journal of Clinical Oncology 2009; 27: 1788-1793. (IF 18.97)
Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H. Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma. Journal of Clinical Oncology 2011; 29(9): 1125-32. (IF 18.97)
Monaghan K, Khong T, Spencer A. The novel JAK2 inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells. Leukemia 2011 Jul 26. doi: 10.1038/leu. 2011.175. [Epub ahead of print] (IF 8.97)
Khong T & Spencer A. Targeting HSP90 induces apoptosis and inhibits critical survival and proliferation pathways in multiple myeloma. Molecular Cancer Therapeutics 2011; 10(10); 1909-17. (IF 5.26)